Sign inCreate account

Report workspace tools

NCT06131398ACTIVE_NOT_RECRUITINGanonymous

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Sponsor

Source record

Amgen

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

AMG 355, Pembrolizumab

Indication / condition

AI-normalized

Advanced Solid Tumors

Intervention

Source record

AMG 355, Pembrolizumab

Source & freshness

Source record

NCT ID

NCT06131398

Original source

ClinicalTrials.gov

Source last updated

May 28, 2026

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06131398

Title

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Sponsor

Amgen

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE1

Condition raw

Advanced Solid Tumors

Condition normalized

Advanced Solid Tumors

Modality raw

small molecule

Modality normalized

small molecule

Target raw

AMG 355, Pembrolizumab

Target normalized

AMG 355, Pembrolizumab

Interventions

AMG 355, Pembrolizumab

Public preview

Source record

The primary objectives of this study are to:

Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors

Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06131398

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE1

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 28, 2026
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06131398

Indication

Advanced Solid Tumors

Modality

small molecule

Target

AMG 355, Pembrolizumab

Intervention

AMG 355, Pembrolizumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.